Oxidative stress in drug-naïve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders
- 567 Downloads
Oxidative stress and immune dysregulation have been linked to schizophrenia and depression. However, it is unknown whether these factors are related to the pathophysiology or whether they are an epiphenomenon. Inconsistent oxidative stress-related findings in previous studies may have resulted from the use of different biomarkers which show disparate aspects of oxidative stress. Additionally, disease severity, medication, smoking, endocrine stress axis activation and obesity are potential confounders. In order to address some of these shortcomings, we have analyzed a broader set of oxidative stress biomarkers in our exploratory study, including urinary 8-iso-prostaglandin F2α (8-iso-PGF2α), 8-OH-2-deoyxguanosine (8-OH-2-dG), and blood levels of malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione S-transferase (GST) in acutely ill drug-naïve first episode patients with schizophrenia (n = 22), major depression (n = 18), and controls (n = 43). Possible confounding factors were considered, and patients were followed-up after 6 weeks of treatment. No differences were observed regarding 8-OH-2-dG, MDA and GST. At baseline, 8-iso-PGF2α levels were higher in patients with schizophrenia (p = 0.004) and major depression (p = 0.037), with a trend toward higher SOD concentrations in schizophrenia (p = 0.053). After treatment, schizophrenia patients showed a further increase in 8-iso-PGF2α (p = 0.016). These results were not related to age, sex, disease severity, medication or adipose tissue mass. However, 8-iso-PGF2α was associated with smoking, endocrine stress axis activation, C-reactive protein levels and low plasma concentrations of brain-derived neurotrophic factor. This study suggests a role of lipid peroxidation particularly in drug-naïve acutely ill schizophrenia patients and highlights the importance of taking into account other confounding factors in biomarker studies.
KeywordsOxidative stress Schizophrenia Depression 8-Iso-prostaglandin F2α Isoprostane Malondialdehyde 8-OH-2-deoyxguanosine Superoxide dismutase Glutathione S-transferase
Anke Dudeck, Gabriela Meyer-Lotz and Jeanette Schadow participated in the sample characterization and collection. Katrin Borucki provided helpful advice during manuscript preparation. This study has been performed without extra funding.
Compliance with ethical standards
Conflicts of interest
SB is a director of Psynova Neurotech Ltd and PsyOmics Ltd. All other authors declare no conflicts of interest.
- 2.APA (2000) Diagnostic and statistical manual of mental disorders, 4th revised edition (dsm-iv-tr). American Psychiatric Press, WashingtonGoogle Scholar
- 7.Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Bush AI (2008) N-acetyl cysteine as a glutathione precursor for schizophrenia–a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 64:361–368CrossRefPubMedGoogle Scholar
- 19.Frijhoff J, Winyard PG, Zarkovic N, Davies SS, Stocker R, Cheng D, Knight AR, Taylor EL, Oettrich J, Ruskovska T, Gasparovic AC, Cuadrado A, Weber D, Poulsen HE, Grune T, Schmidt HH, Ghezzi P (2015) Clinical relevance of biomarkers of oxidative stress. Antioxid Redox Signal 23:1144–1170CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Gaebel W, Falkai P (2005) Interdisciplinary praxis guidelines: AWMF S3 guidelines of the german psychiatric association for schizophrenia. Steinkopff, DarmstadtGoogle Scholar
- 32.Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE, Kolbeck R, Hoppe E, Oropeza-Wekerle RL, Bartke I, Stadelmann C, Lassmann H, Wekerle H, Hohlfeld R (1999) Activated human t cells, b cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 189:865–870CrossRefPubMedPubMedCentralGoogle Scholar
- 56.Schwedhelm E, Tsikas D, Durand T, Gutzki FM, Guy A, Rossi JC, Frolich JC (2000) Tandem mass spectrometric quantification of 8-iso-prostaglandin f2alpha and its metabolite 2,3-dinor-5,6-dihydro-8-iso-prostaglandin f2alpha in human urine. J Chromatogr B Biomed Sci Appl 744:99–112CrossRefPubMedGoogle Scholar
- 58.Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The mini-international neuropsychiatric interview (m.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22–33PubMedGoogle Scholar
- 61.Steiner J, Bogerts B, Sarnyai Z, Walter M, Gos T, Bernstein HG, Myint AM (2012) Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: potential role of glial nmda receptor modulators and impaired blood-brain barrier integrity. World J Biol Psychiatry 13:482–492CrossRefPubMedGoogle Scholar
- 62.Tsikas D, Schwedhelm E, Suchy MT, Niemann J, Gutzki FM, Erpenbeck VJ, Hohlfeld JM, Surdacki A, Frolich JC (2003) Divergence in urinary 8-iso-pgf(2alpha) (ipf(2alpha)-iii, 15-f(2t)-IsoP) levels from gas chromatography-tandem mass spectrometry quantification after thin-layer chromatography and immunoaffinity column chromatography reveals heterogeneity of 8-iso-PGF(2alpha). Possible methodological, mechanistic and clinical implications. J Chromatogr B Analyt Technol Biomed Life Sci 794:237–255CrossRefPubMedGoogle Scholar
- 69.Yamamori H, Hashimoto R, Ishima T, Kishi F, Yasuda Y, Ohi K, Fujimoto M, Umeda-Yano S, Ito A, Hashimoto K, Takeda M (2013) Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (mmp-9) in treatment-resistant schizophrenia treated with clozapine. Neurosci Lett 556:37–41CrossRefPubMedGoogle Scholar